Significance of comorbidities for cardiovascular diseases
Our scientific focus
The influence of comorbidities on coagulation and heart failure
Comorbidities such as diabetes mellitus and chronic kidney disease (CKD) significantly impair the prognosis of patients. Diabetes mellitus is one of the major, continuously increasing public health issues, with approximately 6 million people currently affected by diabetes in Germany. Heart failure is a common complication in patients with diabetes mellitus and is associated with a 7 to 10-fold increased mortality rate. Another risk factor for thromboembolic events and the development of heart failure, which is still only partially understood, is chronic kidney disease. The hearts of patients with diabetes and/or CKD exhibit various metabolic and structural changes, although the molecular mechanisms have not been fully clarified. Consequently, there are no specific therapeutic options available to improve the prognosis of patients with heart failure and diabetes mellitus or CKD. Therefore, we are dedicating ourselves to elucidating the molecular and pathophysiological mechanisms that contribute to the increased cardiovascular morbidity and mortality of patients with diabetes or CKD, both in basic research projects and large clinical studies.
Group Leader
Prof. Dr. med. Katharina Marx-Schütt (geb. Heß), FESC
Oberärztin der Medizinischen Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin
Tel.: 0241 80-80841
Fax: 0241 80-82545
kschuettukaachende
Post Docs
Priv.-Doz. Dr. med. Martin Berger
mbergerukaachende
Dr. Alexandra Buskens-Heinzmann
abuskensheinukaachende
MTA
Katharina Lysaja
klysajaukaachende
Mitarbeitende
Dr. Daniel Roden
drodenukaachende
Selected publications:
- Schuett K, Savvaidis A, Maxeiner S, Lysaja K, Jankowski V, Schirmer SH, Dimkovic N, Boor P, Kaesler N, Dekker FW, Floege J, Marx N, Schlieper G. Clot Structure: A Potent Mortality Risk Factor in Patients on Hemodialysis. J Am Soc Nephrol. 2017 May;28(5):1622-1630.
- Schuett K, Kleber ME, Scharnagl H, Lorkowski S, März W, Niessner A, Marx N, Meinitzer A. Trim\ethylamine-N-oxide (TMAO) and heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2017 Dec 26;70(25):3202-3204.
- Berger M, Kleber ME, Delgado GE, März W, Hellstern P, Meinitzer A, Marx N, Schuett KA. Research Letter: Trimethylamine N-oxide (TMAO) and ADP-induced platelet reactivity are independent risk factors for all-cause and cardiovascular mortality. Circ Res 2020;126(5):660-662
- King RJ*, Schuett K*, Tiede C, Jankowski V, John V, Trehan A, Simmons K ,Ponnambalam S, Storey RF, Fishwick CWG, MJ, Tomlinson DC, Ajjan RA. Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. Haematologica. 2021 Jun 1;106(6):1616-1623. doi:10.3324/haematol.2019.239558.PMID: 32354869
- Berger M, Dressel A, Kleber ME, März W, Hellstern P, Marx N, Schütt K. Platelet Reactivity and Cardiovascular Mortality Risk in the LURIC Study. J Clin Med. 2023 Feb 28;12(5):1913. doi: 10.3390/jcm12051913. PMID: 36902699; PMCID: PMC10003439.
- Schütt, K., Aberle, J., Bauersachs, J., et al. Positionspapier Herzinsuffizienz und Diabetes. Kardiologie (2022) doi.org/10.1007/s12181-022-00562-4
- Schuett K, Marx N, Lehrke M. The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy. Circ Res. 2023 Apr 14;132(8):902-914. doi: 10.1161/CIRCRESAHA.122.321748. Epub 2023 Apr 13. PMID: 37053284
- K, Cherney DZI, Jankowski J, Matsushita K, Nardone M, Marx N. Cardiovascular disease in chronic kidney disease. Eur Heart J. 2025 Jun 16;46(23):2148-2160. doi: 10.1093/eurheartj/ehaf167.
- Berger M, Reugels M, Heinzmann A, Lysaja K, Rizk M, Kern JS, Wolf M, Wolfart S, Jankowski V, Jankowski J, Marx N, Marx-Schütt K. Association of Complement Factor D with Cardiovascular Mortality and Clot Lysis in CKD. J Am Soc Nephrol. 2025 Aug 22. doi: 10.1681/ASN.0000000870. Online ahead of print.
For a complete reference list please see PubMed* Link und
For a complete reference list please see PubMed* Link
